Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ursula A Matulonis

Showing results (31-40 of 236) with videos related to

Pageof 24
Sort By:
Cold Spring Harbor Perspectives in Medicine|May 19, 2025
Ovarian Cancer TherapyDiana Miao, Ursula A Matulonis, Rebecca L Porter
Gynecologic Oncology|March 11, 2014
PARP inhibitors in ovarian cancer: current status and future promiseJoyce F Liu, Panagiotis A Konstantinopoulos, Ursula A Matulonis
Gynecologic Oncology|October 20, 2004
Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactionsChyh-Woei Lee, Ursula A Matulonis, Mariana C Castells
Gynecologic Oncology|February 5, 2018
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicitiesKathleen N Moore, Mansoor Raza Mirza, Ursula A Matulonis
Gynecologic Oncology|August 2, 2005
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 coursesChyh-Woei Lee, Ursula A Matulonis, Mariana C Castells
Gynecologic Oncology|October 3, 2009
Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinomaJoyce F Liu, Michelle S Hirsch, Hang Lee, et al.
Gynecologic Oncology|February 22, 2005
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatmentsAnna M Feldweg, Chyh-Woei Lee, Ursula A Matulonis, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|January 27, 2025
Validation of Tumor Budding as a Prognostic Factor in Ovarian Clear Cell Carcinoma Using an Independent CohortLawrence H Lin, Lina Irshaid, Ursula A Matulonis, et al.
Gynecologic Oncology|October 22, 2019
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutationsJennifer Taylor Veneris, Ursula A Matulonis, Joyce F Liu, et al.
Gynecologic Oncology Reports|February 9, 2019
<i>POLE</i>-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposureElizabeth K Lee, Neal I Lindeman, Ursula A Matulonis, et al.
Pageof 24

Showing results (31-40 of 236) with videos related to

Sort By:
Pageof 24
Cold Spring Harbor Perspectives in Medicine|May 19, 2025
Ovarian Cancer TherapyDiana Miao, Ursula A Matulonis, Rebecca L Porter
Gynecologic Oncology|March 11, 2014
PARP inhibitors in ovarian cancer: current status and future promiseJoyce F Liu, Panagiotis A Konstantinopoulos, Ursula A Matulonis
Gynecologic Oncology|October 20, 2004
Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactionsChyh-Woei Lee, Ursula A Matulonis, Mariana C Castells
Gynecologic Oncology|February 5, 2018
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicitiesKathleen N Moore, Mansoor Raza Mirza, Ursula A Matulonis
Gynecologic Oncology|August 2, 2005
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 coursesChyh-Woei Lee, Ursula A Matulonis, Mariana C Castells
Gynecologic Oncology|October 3, 2009
Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinomaJoyce F Liu, Michelle S Hirsch, Hang Lee, et al.
Gynecologic Oncology|February 22, 2005
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatmentsAnna M Feldweg, Chyh-Woei Lee, Ursula A Matulonis, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|January 27, 2025
Validation of Tumor Budding as a Prognostic Factor in Ovarian Clear Cell Carcinoma Using an Independent CohortLawrence H Lin, Lina Irshaid, Ursula A Matulonis, et al.
Gynecologic Oncology|October 22, 2019
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutationsJennifer Taylor Veneris, Ursula A Matulonis, Joyce F Liu, et al.
Gynecologic Oncology Reports|February 9, 2019
<i>POLE</i>-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposureElizabeth K Lee, Neal I Lindeman, Ursula A Matulonis, et al.
Pageof 24